People with schizophrenia who were treated with Risperdal Consta - a new, long-acting formulation in development of the most widely prescribed antipsychotic, risperidone, experienced significant symptom relief, with relatively low levels of side effects, in a study published in the American Journal of Psychiatry. Chemical Business NewsBase - Press Release via NewsEdge Corporation : People with schizophrenia who were treated with Risperdal Consta - a new, long-acting formulation in development of the most widely prescribed antipsychotic, risperidone, experienced significant symptom relief, with relatively low levels of side effects, in a study published in the American Journal of Psychiatry. In the 12-week, double-blind study, 400 patients with schizophrenia were randomised to receive injections of placebo or Risperdal Consta (25 mg, 50 mg or 75 mg) once every two weeks. Significant improvement was seen at all doses studied in both positive symptoms and negative symptoms. An average of 45% of patients, depending on the dosage administered, saw a 20% or greater degree of symptom improvement. All doses of Risperdal Consta were well tolerated. Patients enrolled in the study were given oral risperidone for one week at the start of the study. Oral treatment continued for another three weeks after the injections began to provide a smooth transition between the oral and injectable formulations. The new, long-acting injectable formulation uses technology developed by Alkermes Inc, of Cambridge, MA, that allows the medication risperidone to be gradually released into the body. Based in Titusville, NJ, Janssen Pharmaceutica Products LP, a wholly owned subsidiary of Johnson & Johnson has a long track record in developing and marketing treatments for central nervous system disorders. Publication: Chemical Business NewsBase - Press Release Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
ФГБНУ НЦПЗ, совместно с РОП, при участии СОПЗ, проводит 6-я Костромскую Всероссийскую школу молодых ученых и специалистов в области психического здоровья «Психические заболевания в условиях современных социальных вызовов: возрастные аспекты» 03 октября, 2024
ФГБНУ НЦПЗ совместно с РОП, при участии СОПЗ, проводит Юбилейную Всероссийскую Научно-практическую конференцию с международным участием, посвященную 80-летию НЦПЗ 06 июня, 2024
ФГБНУ НЦПЗ совместно с РОП проводит Всероссийскую конференции молодых ученых, посвященную 120-летию со дня рождения академика А.В. Снежневского. Во вложенных документах - более подробная информация о конференциях и о возможностях принять участие. 21 мая, 2024
Конференция с международным участием «Биполярное аффективное расстройство: весеннее обострение» 28 марта, 2024
8 февраля отмечается День российской науки. Т.П. Клюшник, д.м.н., профессор, директор ФГБНУ НЦПЗ, поздравила работников Центра с праздником, отметив их ценный вклад в науку, и пожелала новых успехов, идей и открытий. 08 февраля, 2024